Also known as: XGenomes Corp.
XGenomes is building the sequencing technology of the future.
Company is active
Event Year: 2018
Company is active
Event Year: 2018
XGenomes is dedicated to revolutionizing DNA sequencing through the development of cutting-edge technology. Our integrated approach combines innovative biochemistry, advanced hardware, and sophisticated algorithms to provide a streamlined sequencing process. Eliminating the need for library preparation, our technology sequences directly from unadulterated single DNA molecules. Furthermore, DNA extraction is seamlessly integrated with the sequencing process, removing bioinformatics bottlenecks. Our method ensures unprecedented accuracy by incorporating multiple layers of built-in redundancy, including concurrent sequencing of both DNA strands. The resulting sequence data will be comprehensive, encompassing structural and single nucleotide variants, long-range haplotype phase, and the repetitive regions of the genome. With a target cost of goods for consumables below $10, we aim to offer our product at a price point that expands the market while maintaining a margin exceeding 90%. Our initial strategy involves providing sequencing as a service to high-value clients, followed by a razor and blade model involving the sale of instruments and consumables.
XGenomes is dedicated to revolutionizing DNA sequencing through the development of cutting-edge technology. Our integrated approach combines innovative biochemistry, advanced hardware, and sophisticated algorithms to provide a streamlined sequencing process. Eliminating the need for library preparation, our technology sequences directly from unadulterated single DNA molecules. Furthermore, DNA extraction is seamlessly integrated with the sequencing process, removing bioinformatics bottlenecks. Our method ensures unprecedented accuracy by incorporating multiple layers of built-in redundancy, including concurrent sequencing of both DNA strands. The resulting sequence data will be comprehensive, encompassing structural and single nucleotide variants, long-range haplotype phase, and the repetitive regions of the genome. With a target cost of goods for consumables below $10, we aim to offer our product at a price point that expands the market while maintaining a margin exceeding 90%. Our initial strategy involves providing sequencing as a service to high-value clients, followed by a razor and blade model involving the sale of instruments and consumables.
Total Raised: Unknown (Y Combinator backed)
Last Round: Winter 2019
Total Raised: Unknown (Y Combinator backed)
Last Round: Winter 2019
Healthcare
Healthcare
Healthcare -> Diagnostics
Healthcare -> Diagnostics
Team size: 6
Hiring: No
Team size: 6
Hiring: No